Abstract
Outcome after Inotuzumab Ozogamicin for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Extramedullary Disease
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have